🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Reference (R)

Found 279 matching trials

A Single-center, Open, Randomized, Single-dose, Cross-over Bioequivalence Study to Evaluate the Effects of the Test Formulation Abalparatide Injection and the Reference Formulation Abalparatide Injection (Tymlos®) in Healthy Adult Subjects

PHASE1

To investigate the pharmacokinetics of the test preparation abalparatide in...

Status

Not Yet Recruiting

Location

The Affiliated Hospital of Qingdao University

Start Date

2025-01-02

Trial ID

NCT06753864

Treatments Being Tested

Test (T)Reference (R)

Compare the Pharmacokinetics and Safety of CKD-391 With Co-administration of D086 and D337

PHASE1

Compare the pharmacokinetic characteristics and safety between CKD-391 tabl...

Status

Completed

Location

INHA University Hospital

Start Date

2018-09-05

Trial ID

NCT03793985

Treatments Being Tested

T R

A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the Blood

PHASE1

In order to assess the potential impact of steady state BI 425809 on CYP3A ...

Status

Completed

Location

Humanpharmakologisches Zentrum Biberach

Start Date

2022-03-18

Trial ID

NCT05258110

Treatments Being Tested

midazolam iclepertin (BI 425809)

To Assess Safety, Tolerability and Pharmacokinetics of BI 730357 in Healthy Male Volunteers

PHASE1

The primary objective of the Single Rising Dose (SRD) part (trial part 1) i...

Status

Completed

Location

Humanpharmakologisches Zentrum Biberach

Start Date

2017-01-12

Trial ID

NCT03004404

Treatments Being Tested

Placebo BI 730357 BI 730357

Bioequivalence Study of Two Formulations of Sildenafil Tablet 100 mg in Healthy Male Volunteers Under Fasting Conditions

PHASE1

This is an open-labeled (laboratory blinded), randomized, two period, singl...

Status

Unknown

Location

Private healthcare institution "Clinical Hospital "RZD-Medicine" of the city of Yaroslavl"

Start Date

2021-05-10

Trial ID

NCT04882826

Treatments Being Tested

Sildenafil film-coated tablet 100 mg Viagra® film-coated tablet 100 mg

PSYCHIATRIC Disorders and Covid-19

N/A

Given the possible risks and complications of a comorbidity between psychia...

Status

Terminated

Location

Nantes University Hospital - IFAC

Start Date

2020-04-24

Trial ID

NCT04358042

Treatments Being Tested

Brief Psychiatric Rating Scale Depression, Anxiety and Stress Scale Impact of Event Scale-Revised Connor-Davidson Resilience Scale 10 items (CD-RISC 10)

A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers

EARLY_PHASE1

This is a monocentric, randomized, open-label, single-dose, three-cycle, pa...

Status

Completed

Location

Shanghai Xuhui Central Hospital

Start Date

2022-06-01

Trial ID

NCT05318820

Treatments Being Tested

HMPL-523

Tools to Identify People At Risk or Already Infected with HIV and HCV

Wedge-Shaped Clusterded Randomizad Trial to Evaluate Two Tools to identify ...

Status

Unknown

Location

Maria J. Vivancos-Gallego

Start Date

2023-07-01

Trial ID

NCT06528626

Treatments Being Tested

rapid HIV and HCV serological tests

Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer

This study was a multicenter, randomized, open, single-dose, two-cycle, two...

Status

Recruiting

Location

The First Affiliated hospital of Hennan University of Science & Technology

Start Date

2025-03-12

Trial ID

NCT06765590

Treatments Being Tested

T, 260 mg/m2, paclitaxel for injection (albumin-bound)R, 260 mg/m2, paclitaxel for injection (albumin bound).

Clinical Pilot Study in Healthy Men to Characterize the Uptake of Buprenorphine Into and Its Elimination From the Body After Topical Application of Two New Forms of a Skin Patch in Comparison to a Reference Patch

PHASE1

This study is intended to produce information on the pharmacokinetic charac...

Status

Completed

Location

Swiss Pharma Contract

Start Date

2005-11-07

Trial ID

NCT03785613

Treatments Being Tested

Test Product T1: Buprenorphine patch (9 mg)Test Product T2: Buprenorphine patch (3.8 mg)Reference Product R: Transtec patch (20 mg)Matching placebo patch to T1 Matching placebo patch to T2 Matching placebo patch to R

Previous Next